Skip to main content
Advertisement
Advertisement

IKT

IKT logo

Inhibikase Therapeutics, Inc. Common Stock

2.15
USD
Sponsored
-0.16
-6.93%
Sep 23, 15:45 UTC -4
Closed
exchange

After-Market

2.15

0.00
+0.23%

IKT Earnings Reports

Positive Surprise Ratio

IKT beat 11 of 21 last estimates.

52%

Next Report

Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.11
Implied change from Q2 26 (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
-15.38%

Inhibikase Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 11, 2026, IKT reported earnings of -0.11 USD per share (EPS) for Q2 26, missing the estimate of -0.10 USD, resulting in a -1.76% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.04% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Inhibikase Therapeutics, Inc. Common Stock reported EPS of -$0.11, missing estimates by -1.76%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.04%, changed from $2.45 before the earnings release to $2.40 the day after.
The next earning report is scheduled for Nov 12, 2026.
Based on 4 analysts, Inhibikase Therapeutics, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement